The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Previous studies in people with obesity-associated heart failure with preserved ejection fraction showed greater improvements in 6-minute walk distance and quality of life measures and preliminary evidence of a reduction in cardiovascular events, though these studies were small and relatively short in duration.
“This has been evidenced by demonstrating greater improvements in 6-minute walk distance and quality of life measures and preliminary evidence of a reduction in CV events in these studies, which were small and relatively short in duration.”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [14]
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredPrevious studies have demonstrated favourable effects of semaglutide and tirzepatide in people with obesity-associated heart failure with preserved ejection fraction.
“Previous studies have demonstrated favourable effects of both the GLP-1 receptor agonist, semaglutide, and the GIP/GLP-1 receptor agonist, tirzepatide, in people with obesity associated HFpEF.6,[13][14][15]”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [14]
These findings were present in patients with or without type 2 diabetes.
“These findings were present in patients with or without T2D.14,15”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [14]
The greater weight loss achieved with tirzepatide versus dulaglutide in this trial may be relevant to the quality-of-life findings, given that greater weight loss has been associated with greater KCCQ benefits in prior studies of incretins in patients with heart failure with preserved ejection fraction.
“The greater weight loss achieved with tirzepatide vs. dulaglutide in this trial may be relevant to these findings, given that greater weight loss has been associated with greater KCCQ benefits in prior studies of incretins in patients living with HFpEF.[13][14][15]”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationTirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Self-citationEffect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
Mohammed, S. F., Hussain, S., Mirzoyev, S. A., Edwards, W. D., Maleszewski, J. J., & Redfield, M. M. (2015) · Circulation · doi:10.1161/circulationaha.114.009625 · Cited by 874
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationButler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386
Self-citationVerbrugge, F. H., Omote, K., Reddy, Y. N. V., Sorimachi, H., Obokata, M., & Borlaug, B. A. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab911 · Cited by 214
Self-citationHusain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.001 · Cited by 200
Self-citationPacker, M., Lam, C. S. P., Lund, L. H., Maurer, M. S., & Borlaug, B. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1902 · Cited by 185
Self-citationLovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168
Kosiborod, M. N., Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Jon Jensen, T., Rasmussen, S., Erlang Marstrand, P., Petrie, M. C., Shah, S. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067505 · Cited by 104
Self-citationIncreased Epicardial Adipose Tissue Thickness in Type 2 Diabetes Mellitus and Obesity
Song, D. K., Hong, Y. S., Lee, H., Oh, J.-Y., Sung, Y.-A., & Kim, Y. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.5.405 · Cited by 80
Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072679 · Cited by 74
Self-citationQin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K. (2024) · Endocrine · doi:10.1007/s12020-024-03896-z · Cited by 55
Xie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
Flagged first, then by citations
Research works printed but not linked: 47
- Nichols, 2004, The incidence of congestive heart failure in type 2 diabetes: an update, Diabetes Care, 27, 1879, 10.2337/diacare.27.8.1879 · DOI · Paper page
- Ingelsson, 2005, Insulin resistance and risk of congestive heart failure, JAMA, 294, 334, 10.1001/jama.294.3.334 · DOI
- Packer, 2018, Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes, Diabetes Care, 41, 11, 10.2337/dci17-0052 · DOI
- Patel, 2022, Diabetes status modifies the association between different measures of obesity and heart failure risk among older adults: a pooled analysis of community-based NHLBI cohorts, Circulation, 145, 268, 10.1161/CIRCULATIONAHA.121.055830 · DOI
- Vuori, 2021, Diabetes status-related differences in risk factors and mediators of heart failure in the general population: results from the MORGAM/BiomarCaRE consortium, Cardiovasc Diabetol, 20, 195, 10.1186/s12933-021-01378-4 · DOI
- Campbell, 2019, Threshold body mass index and sex-specific waist circumference for increased risk of heart failure with preserved ejection fraction, Eur J Prev Cardiol, 26, 1594, 10.1177/2047487319851298 · DOI
- Deanfield, 2024, Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial, Lancet, 404, 773, 10.1016/S0140-6736(24)01498-3 · DOI
- Neves, 2025, Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: the EXSCEL trial, Eur J Heart Fail, 27, 540, 10.1002/ejhf.3478 · DOI
- Packer, 2018, Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity, Circulation, 137, 1614, 10.1161/CIRCULATIONAHA.117.032474 · DOI · Paper page
- Obokata, 2017, Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction, Circulation, 136, 6, 10.1161/CIRCULATIONAHA.116.026807 · DOI · Paper page
- Rao, 2020, Regional adiposity and heart failure with preserved ejection fraction, Eur J Heart Fail, 22, 1540, 10.1002/ejhf.1956 · DOI
- Castro-Barquero, 2023, Loss of visceral fat is associated with a reduction in inflammatory status in patients with metabolic syndrome, Mol Nutr Food Res, 67, 10.1002/mnfr.202200264 · DOI
- Yang, 2024, Long-term outcomes prediction in diabetic heart failure with preserved ejection fraction by cardiac MRI, Eur Radiol, 34, 5678, 10.1007/s00330-024-10658-y · DOI
- Wolsk, 2024, Coronary microvascular dysfunction and left heart filling pressures in patients with type 2 diabetes, ESC Heart Fail, 11, 3551, 10.1002/ehf2.14929 · DOI
- Gulsin, 2019, Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes, Ther Adv Endocrinol Metab, 10.1177/2042018819861593 · DOI
- Filippatos, 2022, Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes, Circulation, 146, 676, 10.1161/CIRCULATIONAHA.122.059785 · DOI · Paper page
- Lejeune, 2021, Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort, Cardiovasc Diabetol, 20, 48, 10.1186/s12933-021-01242-5 · DOI
- Adamson, 2022, Dapagliflozin for heart failure according to body mass index: the DELIVER trial, Eur Heart J, 43, 4406, 10.1093/eurheartj/ehac481 · DOI
- Kosiborod, 2024, Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials, Lancet, 404, 949, 10.1016/S0140-6736(24)01643-X · DOI
- Jamaly, 2024, Incidence of type 2 diabetes after gastric by-pass surgery in a Swedish controlled cohort study, Obes Res Clin Pract, 18, 15, 10.1016/j.orcp.2023.12.001 · DOI
- Höskuldsdóttir, 2021, J Am Heart Assoc, 10, 10.1161/JAHA.120.019323 · DOI · Paper page
- Wang, 2005, Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study, Int J Clin Pract, 59, 746, 10.1111/j.1368-5031.2005.00568.x · DOI
- Chen, 2024, Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K/Akt signaling, Peptides, 178, 10.1016/j.peptides.2024.171245 · DOI
- Park, 2024, GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage, Am J Physiol Heart Circ Physiol, 326, H1159, 10.1152/ajpheart.00574.2023 · DOI
- Solomon, 2024, Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure, J Am Coll Cardiol, 84, 1587, 10.1016/j.jacc.2024.08.021 · DOI · Paper page
- Kawel-Boehm, 2021, Reference ranges (“normal values”) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update, J Cardiovasc Magn Reson, 23, 114, 10.1186/s12968-021-00815-3 · DOI
- Inzucchi, 2022, Lancet Diabetes Endocrinol, 10, 869, 10.1016/S2213-8587(22)00308-4 · DOI
- Peikert, 2022, Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF, Eur J Heart Fail, 24, 794, 10.1002/ejhf.2450 · DOI
- Berisha-Muharremi, 2022, Diabetes is the strongest predictor of limited exercise capacity in chronic heart failure and preserved ejection fraction (HFpEF), Front Cardiovasc Med, 9, 10.3389/fcvm.2022.883615 · DOI
- Shi, 2021, Effect of diabetes mellitus on the development of left ventricular contractile dysfunction in women with heart failure and preserved ejection fraction, Cardiovasc Diabetol, 20, 185, 10.1186/s12933-021-01379-3 · DOI
- Nan Tie, 2024, The impact of diabetes on haemodynamic and cardiometabolic responses in heart failure with preserved ejection fraction, Heart Lung Circ, 33, 376, 10.1016/j.hlc.2023.12.008 · DOI
- Sugita, 2023, Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction: a case-control study in individuals aged 65-80 years, Cardiovasc Diabetol, 22, 97, 10.1186/s12933-023-01835-2 · DOI
- Lin, 2021, Epicardial adiposity in relation to metabolic abnormality, circulating adipocyte FABP, and preserved ejection fraction heart failure, Diagnostics (Basel), 11, 397, 10.3390/diagnostics11030397 · DOI
- Goldman, 2023, Uncovering the role of epicardial adipose tissue in heart failure with preserved ejection fraction, JACC Adv, 2, 10.1016/j.jacadv.2023.100657 · DOI
- Myasoedova, 2023, Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis, Cardiovasc Diabetol, 22, 23, 10.1186/s12933-023-01738-2 · DOI · Paper page
- Fukuta, 2024, Association of epicardial fat with cardiac structure and function and exercise capacity in heart failure with preserved ejection fraction: a systematic review and meta-analysis, Int J Cardiol Heart Vasc, 54
- Sidhu, 2024, Epicardial fat in heart failure with preserved ejection fraction compared with reduced ejection fraction, J Clin Med, 13, 5533, 10.3390/jcm13185533 · DOI
- Shao, 2024, Epicardial adipose tissue in obesity with heart failure with preserved ejection fraction: Cardiovascular magnetic resonance biomarker study, World J Cardiol, 16, 149, 10.4330/wjc.v16.i3.149 · DOI
- Venkateshvaran, 2022, Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS-HFpEF study, Eur J Heart Fail, 24, 2251, 10.1002/ejhf.2709 · DOI
- Correia, 2022, Epicardial adipose tissue in heart failure phenotypes—a meta-analysis, Arq Bras Cardiol, 118, 625
- Pugliese, 2021, Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure, Eur J Heart Fail, 23, 1858, 10.1002/ejhf.2337 · DOI
- Gorter, 2020, Epicardial adipose tissue and invasive hemodynamics in heart failure with preserved ejection fraction, JACC Heart Fail, 8, 667, 10.1016/j.jchf.2020.06.003 · DOI
- Lobeek, 2024, Epicardial adipose tissue and exercise intolerance in HFpEF, Int J Cardiol Heart Vasc, 54
- Manubolu, 2024, Effect of semaglutide on epicardial adipose tissue in type 2 diabetes: insights from the STOP (Semaglutide Treatment effect On coronary atherosclerosis Progression) randomized trial, J Am Coll Cardiol, 84, 865, 10.1016/j.jacc.2024.05.065 · DOI · Paper page
- Morano, 2015, Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study, Acta Diabetol, 52, 727, 10.1007/s00592-014-0710-z · DOI · Paper page
- Verma, 2024, Inflammation in obesity-related HFpEF: the STEP-HFpEF program, J Am Coll Cardiol, 84, 1646, 10.1016/j.jacc.2024.08.028 · DOI
- Malavazos, 2023, Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies, Eur J Prev Cardiol, 30, 680, 10.1093/eurjpc/zwad050 · DOI · Paper page
Cited by
Sorted by citations
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Franco, D. R., Kahn, S. E., Lincoff, A. M., Martins, R. F., McGuire, D. K., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag452
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., DiMaria, J. M., Baum, S. J., Litwin, S. E., Murakami, M., Zhou, C., Ou, Y., Koeneman, L., & Borlaug, B. A.
- Venue
- JACC
- Publisher
- Elsevier BV
- Published
- 2025-09
- Volume
- 86
- Issue
- 10
- Pages
- 696-707
- ISSN
- 0735-1097
- Cited by
- 34
- References
- 22
- Language
- en
- Licence
- Funders
- Eli Lilly and Co
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
